{
  "id": "adv_mhgap#referral_8eb2e9a0",
  "content": "y There was no evidence for maintenance therapy in LMICs and in supply chain interruption such\nfor more than two years and evidence was scarce as during emergencies) may interfere with\nbetween one- and two-year follow-up. More studies continuation of treatment. Reliability of supply\nare required on longer term maintenance. should inform choice of medicine.\ny More studies applying gradual tapering of the y For the treatment of psychotic disorders, the WHO\nantipsychotic in the placebo group are needed. EML (13) includes:\n– fluphenazine (therapeutic alternatives:\nImplementation considerations haloperidol decanonate, zuclopenthixol\ny As individuals with a first psychotic episode usually decanonate);\nrespond well to antipsychotics, drug choice should – haloperidol (therapeutic alternative:\nbe mainly based on side-effect profiles. chlorpromazine);\ny People living with schizophrenia should – haloperidol injection;\nbe involved in drug choice in a supported\n– olanzapine;\ndecision-making process.\n– paliperidone (therapeutic alternative:\ny Treatment with antipsychotic medicines should\nrisperidone injection);\nbe combined with psychosocial interventions (see\n– risperidone (therapeutic alternatives: aripiprazole,\nother PICO questions in this module).\nolanzapine, paliperidone, quetiapine);\ny Acquisition costs can differ substantially. Also,\n– complementary list: clozapine.\nthroughout the world, second-generation and other\nPSY3. In adults with bipolar disorder in remission, how long should",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "referral",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Referral y There was no evidence for maintenance therapy in LMICs and in supply chain interruption such\nfor more than two years and evidence was scarce as during emergencies) may interfere with\nbetween one- and two-year follow-up. More studies continuation of treatment. Reliability of supply\nare required on longer term maintenance. should inform choice of medicine.\ny More studies applying gradual tapering of the y For the treatment of psychotic disorders, the WHO\nantipsychotic in the placebo group are needed. EML (13) includes:\n– fluphenazine (therapeutic alternatives:\nImplementation considerations haloperidol decanonate, zuclopenthixol\ny As individuals with a first psychotic episode usually decanonate);\nrespond well to antipsychotics, drug choice should – haloperidol (therapeutic alternative:\nbe mainly based on side-effect profiles. chlorpromazine);\ny People living with schizophrenia should – haloperidol injection;\nbe involved in drug choice in a supported\n– olanzapine;\ndecision-making process.\n– paliperidone (therapeutic alternative:\ny Treatment with antipsychotic medicines should\nrisperidone injection);\nbe combined with psychosocial interventions (see\n– risperidone (therapeutic alternatives: aripiprazole,\nother PICO questions in this module).\nolanzapine, paliperidone, quetiapine);\ny Acquisition costs can differ substantially. Also,\n– complementary list: clozapine.\nthroughout the world, second-generation and other\nPSY3. In adults with bipolar disorder in remission, how long should Y there was no evidence for maintenance therapy in lmics and in supply chain interruption such\nfor more than two years and evidence was scarce as during emergencies) may interfere with\nbetween one- and two-year follow-up..."
}